Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Eric M. Bennett"'
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Deep learning, aided by the availability of big data sets, has led to substantial advances across many disciplines. However, many scientific problems of practical interest lack sufficiently large datasets amenable to deep learning. Predictio
Externí odkaz:
https://doaj.org/article/a93fb3dd2e4e41efb9a611fb0a9f6137
Autor:
Emily K. Makowski, Hongwei Chen, Matthew Lambert, Eric M. Bennett, Nicole S. Eschmann, Yulei Zhang, Jennifer M. Zupancic, Alec A. Desai, Matthew D. Smith, Wenjia Lou, Amendra Fernando, Timothy Tully, Christopher J. Gallo, Laura Lin, Peter M. Tessier
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Self-association governs the viscosity and solubility of therapeutic antibodies in high-concentration formulations used for subcutaneous delivery, yet it is difficult to reliably identify candidates with low self-association during antibody discovery
Externí odkaz:
https://doaj.org/article/b7a6b619288444029f50f9d427dbd60c
Autor:
Sharon M. Campbell, Joseph DeBartolo, James R. Apgar, Lydia Mosyak, Virginie McManus, Sonia Beyer, Eric M. Bennett, Matthew Lambert, Orla Cunningham
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Despite substantial technological advances in antibody library and display platform development, the number of approved biotherapeutics from displayed libraries remains limited. In vivo, 20–50% of peripheral B cells undergo a process of receptor ed
Externí odkaz:
https://doaj.org/article/1a3148ad6bc644088284dab2ad0a2c77
Autor:
James R Apgar, Amy S P Tam, Rhady Sorm, Sybille Moesta, Amy C King, Han Yang, Kerry Kelleher, Denise Murphy, Aaron M D'Antona, Guoying Yan, Xiaotian Zhong, Linette Rodriguez, Weijun Ma, Darren E Ferguson, Gregory J Carven, Eric M Bennett, Laura Lin
Publikováno v:
PLoS ONE, Vol 15, Iss 5, p e0232713 (2020)
For an antibody to be a successful therapeutic many competing factors require optimization, including binding affinity, biophysical characteristics, and immunogenicity risk. Additional constraints may arise from the need to formulate antibodies at hi
Externí odkaz:
https://doaj.org/article/cc94f4a62bcb4df1920dad454aac1825
Autor:
Puja Sapra, Hans-Peter Gerber, Christopher J. O'Donnell, Frank Loganzo, Edward Rosfjord, Judy Lucas, Lioudmila Tchistiakova, Frank Barletta, Tracey Clark, Martin Finkelstein, Hadi Falahatpisheh, Magali Guffroy, George Hu, Cynthia M. Rohde, Christine Hosselet, Jonathon Golas, Manoj B. Charati, Eric M. Bennett, Jeffrey Casavant, Jack Bikker, L. Nathan Tumey, Sujiet Puthenveetil, Kimberly Marquette, Bitha Narayanan, Dangshe Ma, Matthew Sung, Edmund I. Graziani
Effects of Systemic Administration of Free Payload Compared with Conventional HER2-vc0101 on Indicators of Bone Marrow Toxicity and Bone Marrow Payload Levels in Rats
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d432b6130242412350911c126917be78
https://doi.org/10.1158/1535-7163.22520919.v1
https://doi.org/10.1158/1535-7163.22520919.v1
Autor:
Puja Sapra, Hans-Peter Gerber, Christopher J. O'Donnell, Frank Loganzo, Edward Rosfjord, Judy Lucas, Lioudmila Tchistiakova, Frank Barletta, Tracey Clark, Martin Finkelstein, Hadi Falahatpisheh, Magali Guffroy, George Hu, Cynthia M. Rohde, Christine Hosselet, Jonathon Golas, Manoj B. Charati, Eric M. Bennett, Jeffrey Casavant, Jack Bikker, L. Nathan Tumey, Sujiet Puthenveetil, Kimberly Marquette, Bitha Narayanan, Dangshe Ma, Matthew Sung, Edmund I. Graziani
The approval of ado-trastuzumab emtansine (T-DM1) in HER2+ metastatic breast cancer validated HER2 as a target for HER2-specific antibody–drug conjugates (ADC). Despite its demonstrated clinical efficacy, certain inherent properties within T-DM1 ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a1b894a20379dc9a76f654d4811688b
https://doi.org/10.1158/1535-7163.c.6542832
https://doi.org/10.1158/1535-7163.c.6542832
Autor:
Puja Sapra, Hans-Peter Gerber, Christopher J. O'Donnell, Frank Loganzo, Edward Rosfjord, Judy Lucas, Lioudmila Tchistiakova, Frank Barletta, Tracey Clark, Martin Finkelstein, Hadi Falahatpisheh, Magali Guffroy, George Hu, Cynthia M. Rohde, Christine Hosselet, Jonathon Golas, Manoj B. Charati, Eric M. Bennett, Jeffrey Casavant, Jack Bikker, L. Nathan Tumey, Sujiet Puthenveetil, Kimberly Marquette, Bitha Narayanan, Dangshe Ma, Matthew Sung, Edmund I. Graziani
Immunohistochemical evaluation of HER2 expression in vivo cell line and patient-derived xenograft models.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d3ff9f7c862c417038a9aae79602e4f
https://doi.org/10.1158/1535-7163.22520937
https://doi.org/10.1158/1535-7163.22520937
Autor:
Puja Sapra, Hans-Peter Gerber, Christopher J. O'Donnell, Frank Loganzo, Edward Rosfjord, Judy Lucas, Lioudmila Tchistiakova, Frank Barletta, Tracey Clark, Martin Finkelstein, Hadi Falahatpisheh, Magali Guffroy, George Hu, Cynthia M. Rohde, Christine Hosselet, Jonathon Golas, Manoj B. Charati, Eric M. Bennett, Jeffrey Casavant, Jack Bikker, L. Nathan Tumey, Sujiet Puthenveetil, Kimberly Marquette, Bitha Narayanan, Dangshe Ma, Matthew Sung, Edmund I. Graziani
Includes Supplementary Materials and Methods, Data and Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03aca1bc8d20f2fe143c7aa7d3d27294
https://doi.org/10.1158/1535-7163.22520934
https://doi.org/10.1158/1535-7163.22520934
Autor:
Virginie McManus, James R. Apgar, Sonia Beyer, Sharon M. Campbell, Orla Cunningham, Matthew Allister Lambert, Joseph DeBartolo, Eric M. Bennett, Lydia Mosyak
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Despite substantial technological advances in antibody library and display platform development, the number of approved biotherapeutics from displayed libraries remains limited. In vivo, 20–50% of peripheral B cells undergo a process of receptor ed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bef042e6579ef41eb38db2550fa9431
https://pubmed.ncbi.nlm.nih.gov/33557673
https://pubmed.ncbi.nlm.nih.gov/33557673
Autor:
Kimberly Ann Marquette, Frank Loganzo, Puja Sapra, Dangshe Ma, George Hu, Sujiet Puthenveetil, Cynthia M. Rohde, Judy Lucas, L. Nathan Tumey, Matthew Sung, Christine Hosselet, Jonathon Golas, Manoj Charati, Edmund I. Graziani, Frank Barletta, Magali Guffroy, Martin Finkelstein, Jeffrey M. Casavant, Hadi Falahatpisheh, Bitha Narayanan, Jack A. Bikker, Hans-Peter Gerber, Eric M. Bennett, Lioudmila Tchistiakova, Tracey Clark, Edward Rosfjord, Christopher J. O’Donnell
Publikováno v:
Molecular cancer therapeutics. 19(10)
The approval of ado-trastuzumab emtansine (T-DM1) in HER2+ metastatic breast cancer validated HER2 as a target for HER2-specific antibody–drug conjugates (ADC). Despite its demonstrated clinical efficacy, certain inherent properties within T-DM1 ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2262d08bf90166d80d9c9b49e52ffe5a
https://pubmed.ncbi.nlm.nih.gov/32747418
https://pubmed.ncbi.nlm.nih.gov/32747418